Michael Page BSc

At Alexion, Mike Page leads a global team which develops and executes of regulatory strategies across the company’s rare disease product portfolio. Prior to joining Alexion, Mike led the US Regulatory team for oncology at Eisai and the regulatory aspects of Eisai’s monoclonal antibody products. Prior to that, Mike was a regulatory affairs consultant at United BioSource Corporation, before which he was a Director of Regulatory Strategy at Pfizer, both in the UK and the US. Focusing mainly on late-stage development and product registration, Mike has global experience in therapeutic areas including oncology, hematology, psychiatry, neurology, sexual health, and addiction disorders.